Enterprise Value
118.3M
Cash
76.68M
Avg Qtr Burn
-11.83M
Short % of Float
6.91%
Insider Ownership
2.16%
Institutional Own.
24.63%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Iomab-B (CD45) (apamistamab-I-131) Details Hematopoietic cell transplantation , Acute myeloid leukemia | BLA Submission | |
Actimab-A + venetoclax Details Relapsed/refractory acute myeloid leukemia | Phase 1/2 Update | |
Iomab-ACT (CAR-T – CD45) Details Lymphoma, Diffuse large B cell lymphoma | Phase 1/2 Update | |
Actimab-A + CLAG-M Details Relapsed/refractory acute myeloid leukemia | Phase 1 Update | |
Iomab-ACT (GeneTx – CD45) Details Lymphoma, Acute radiation syndrome | Failed Discontinued | |
Actimab-A + venetoclax Details Myelodysplastic syndrome | Failed Discontinued |